The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The relation between PI3K/AKT signalling pathway and cancer
Open accessAbstract
Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to the extracellular stimulators. Hyperactivation of PI3K signalling cascades is one among the most ordinary events in human cancers. Focusing on the PI3K pathway remains both a chance and a challenge for cancer therapy. The high recurrence of phosphoinositide 3-kinase (PI3K) pathway adjustments in cancer has led to a surge in the progression of PI3K inhibitors. Recent developments incorporate a re-assessment of the oncogenic mechanisms behind PI3K pathway modifications. Receptor tyrosine kinases upstream of PI3K, the p110a catalytic fractional unit of PI3K, the downstream kinase, AKT, and therefore the negative regulator, PTEN, are all often altered in cancer. In this review, we consider about the phosphoinositide 3-kinases family and mechanisms of PI3K-Akt stimulation in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Mechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Biology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., & Roberts, T. M. (1985) · Nature · doi:10.1038/315239a0 · Cited by 810
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, L., & Roberts, T. M. (1987) · Cell · doi:10.1016/0092-8674(87)90168-1 · Cited by 646
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Self-citationMutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Brazil, D. P., Park, J., & Hemmings, B. A. (2002) · Cell · doi:10.1016/s0092-8674(02)01083-8 · Cited by 537
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 528
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G. A., & Backer, J. M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1379 · Cited by 520
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 507
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
The Akt kinases: Isoform specificity in metabolism and cancer
Gonzalez, E., & McGraw, T. E. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9335 · Cited by 472
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 468
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Guo, C., Sah, J. F., Beard, L., Willson, J. K. V., Markowitz, S. D., & Guda, K. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20596 · Cited by 396
Classes of phosphoinositide 3-kinases at a glance
Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 379
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Balsara, B. R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 295
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806514106 · Cited by 290
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models
Carnero, A., & Paramio, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00252 · Cited by 233
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s89967 · Cited by 229
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214
Meng, Q., Xia, C., Fang, J., Rojanasakul, Y., & Jiang, B.-H. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.019 · Cited by 214
Vasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Wang, H. Q., Altomare, D. A., Skele, K. L., Poulikakos, P. I., Kuhajda, F. P., Di Cristofano, A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208463 · Cited by 198
PI3-kinase inhibition: a target for drug development?
Stein, R. C., & Waterfield, M. D. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01770-6 · Cited by 192
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer
Spangle, J. M., Roberts, T. M., & Zhao, J. J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.002 · Cited by 172
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9198-3 · Cited by 168
Bertelsen, B. I., Steine, S. J., Sandvei, R., Molven, A., & Lærum, O. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21461 · Cited by 167
PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations☆
Velasco, A., Bussaglia, E., Pallarés, J., Dolcet, X., Llobet‐Navàs, D., Encinas, M., Llecha, N., PALACIOS, J., Prat, J., & Matías‐Guiu, X. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.05.007 · Cited by 160
Regulation and cellular functions of class II phosphoinositide 3-kinases
Falasca, M., & Maffucci, T. (2012) · Biochemical Journal · doi:10.1042/bj20120008 · Cited by 158
Posttranslational regulation of Akt in human cancer
Chan, C., Jo, U., Kohrman, A. Q., Rezaeian, A. H., Chou, P.-C., Logothetis, C. J., & Lin, H. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-59 · Cited by 155
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Zinda, M. J., Johnson, M., Paul, J., Horn, C. L., Konicek, B. W., Lü, Z., Sandusky, G. E., Thomas, J. E., Neubauer, B. L., Lai, M. T., et al. (2001) · PubMed · Cited by 148
Velho, S., Moutinho, C., Cirnes, L., Albuquerque, C. M., Hamelin, R., Schmitt, F. C., Carneiro, F., Oliveíra, C., & Seruca, R. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-255 · Cited by 145
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 136
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 135
Wick, M. J., Dong, L., Riojas, R. A., Ramos, F. J., & Liu, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003937200 · Cited by 134
Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma
Chadha, K. S., Khoury, T., Yu, J., Black, J. D., Gibbs, J. F., Kuvshinoff, B. W., Tan, D., Brattain, M. G., & Javle, M. M. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.07.011 · Cited by 133
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
Dunlap, J. B., Le, C., Shukla, A., Patterson, J., Presnell, A., Heinrich, M. C., Corless, C. L., & Troxell, M. L. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0406-1 · Cited by 122
Polyoma virus middle T antigen and its role in identifying cancer-related molecules
Dilworth, S. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc946 · Cited by 116
Martelli, A. M., Evangelisti, C., Follo, M., Ramazzotti, G., Fini, M., Giardino, R., Manzoli, L., McCubrey, J. A., & Cocco, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011201 · Cited by 116
Tanno, S., Yanagawa, N., Habiro, A., Koizumi, K., Nakano, Y., Osanai, M., Mizukami, Y., Okumura, T., Testa, J. R., & Kohgo, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1788 · Cited by 113
Askham, J. M., Platt, F. M., Chambers, P. A., Snowden, H. H., Taylor, C. F., & Knowles, M. A. (2009) · Oncogene · doi:10.1038/onc.2009.315 · Cited by 110
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 108
Hudis, C. A., Swanton, C., Janjigian, Y. Y., Lee, R., Sutherland, S., Lehman, R. J., Chandarlapaty, S., Hamilton, N., Gajria, D., Knowles, J., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3577 · Cited by 107
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
Lebwohl, D., Anak, Ö., Sahmoud, T., Klimovsky, J., Elmroth, I., Haas, T., Posluszny, J. A., Saletan, S., & Berg, W. J. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12122 · Cited by 97
Santis, G. D., Miotti, S., Mazzi, M., Canevari, S., & Tomassetti, A. (2009) · Oncogene · doi:10.1038/onc.2008.470 · Cited by 97
PI3Kinase signaling in glioblastoma
Lino, M. M., & Merlo, A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0442-z · Cited by 91
Class III PI3K Vps34: essential roles in autophagy, endocytosis, and heart and liver function
Jaber, N. L., & Zong, W. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12026 · Cited by 82
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo
Luwor, R. B., Baradaran, B., Taylor, L. E., Iaria, J., Nheu, T. V., Amiry, N., Hovens, C. M., Wang, B., Kaye, A. H., & Zhu, H.-J. (2012) · Oncogene · doi:10.1038/onc.2012.260 · Cited by 82
Self-citationPhytochemicals and PI3K Inhibitors in Cancer—An Insight
Suvarna, V., Murahari, M., Khan, T. A., Chaubey, P., & Sangave, P. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00916 · Cited by 67
Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Hudes, G. R., Berkenblit, A., Feingold, J. M., Atkins, M. B., Rini, B. I., & Dutcher, J. P. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.10.013 · Cited by 65
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma
Ollikainen, M., Gylling, A., Puputti, M., Nupponen, N. N., Abdel‐Rahman, W. M., Bützow, R. C., & Peltomäki, P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22768 · Cited by 62
Elevated PI3K signaling drives multiple Breast Cancer subtypes
Adams, J. R., Schachter, N. F., Liu, J. C., Zacksenhaus, E., & Egan, S. E. (2011) · Oncotarget · doi:10.18632/oncotarget.285 · Cited by 60
Kobayashi, I., Semba, S., Matsuda, Y., Kuroda, Y., & Yokozaki, H. (2006) · Pathobiology · doi:10.1159/000093087 · Cited by 59
Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis
Brazzatti, J. A., Klingler‐Hoffmann, M., Haylock‐Jacobs, S., Harata‐Lee, Y., Niu, M., Higgins, M. D., Kochetkova, M., Hoffmann, P., & McColl, S. R. (2011) · Oncogene · doi:10.1038/onc.2011.414 · Cited by 54
Sheikh, S. E., Domin, J., Tomtitchong, P., Abel, P. D., Stamp, G., & Lalani, E. (2003) · BMC Clinical Pathology · doi:10.1186/1472-6890-3-4 · Cited by 48
Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells
Kong, Y., Kumar, S. M., & Xu, X. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0418-rar.1 · Cited by 43
PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
Vanhaesebroeck, B., & Khwaja, A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.012 · Cited by 35
Abe, M., Setoguchi, Y., Tanaka, T., Awano, W., Takahashi, K., Ueda, R., Nakamura, A., & Goto, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007306 · Cited by 25
Baghbani, E., Baradaran, B., Pak, F., Mohammadnejad, L., Shanehbandi, D., Mansoori, B., Khaze, V., Montazami, N., Mohammadi, A., & Kokhaei, P. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.124 · Cited by 23
Self-citationDoustvandi, M. A., Mohammadnejad, F., Mansoori, B., Mohammadi, A., Navaeipour, F., Baradaran, B., & Tajalli, H. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.09.020 · Cited by 22
Self-citation
Cited by
Wang, L., Li, S., Luo, H., Lu, Q., & Yu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02477-0 · Cited by 271
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Metadata
- Authors
- Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 698
- Pages
- 120-128
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2919429412
- Cited by
- 651
- References
- 114
- FWCI
- 17.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.